Trading in Novo Nordisk shares by board members, executives and associated persons on 15 February 2021
February 16 2021 - 10:13AM
Trading in Novo Nordisk shares by board members, executives and
associated persons on 15 February 2021
Bagsværd, Denmark, 16 February 2021 — This
document discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Kasim Kutay |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
Identification code |
Novo Nordisk B DK0060534915 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 463.11 |
552 shares |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
552 sharesDKK 463.11 |
e) |
Date of the transaction |
2021-02-15 |
f) |
Place of the transaction |
Nasdaq Copenhagen |
Definitions and background information:
PublicationPublication shall take place no
later than three working days after the trading by board members,
executives or their associated persons. Publication is only
required when the total amount of transactions of a specific board
member/executive or his/her associated persons in any one calendar
year has reached EUR 20,000 (calculated individually).
Who are board members, executives and associated
persons?Board members and executives are members of the
Board of Directors and Executive Management, respectively, of Novo
Nordisk A/S. Associated persons are defined as the following
persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) Other
relatives defined as brothers, sisters, parents, grandparents,
children, grandchildren, cousins etc. who have shared the same
household with a board member or executive for a period of at least
one year on the date of the given transaction and 4) any legal
persons, trust, or partnership, the managerial responsibilities of
which are discharged by a board member/executive or by a person
referred to in items 1)-3) above, or which is directly or
indirectly controlled by such a person, or which is set up for the
benefit of such a person, or the economic interests of which are
substantially equivalent to those of such a person.
What is trading/transaction?Trading is any kind
of transaction, including shares and share related securities
purchased or otherwise acquired, sold or otherwise disposed, gifts,
mortgages, heritage and grants, allotments and exercise of
options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?Date of
transaction is the actual transaction date. The place of
transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and
aggregated information?The volume of transaction is the
number of shares (of DKK 0.20 nominal value) or other financial
instruments traded. In case of a single transaction the price is
the price of that single transaction. In case of multiple
transactions, when the transactions relate to the same financial
instrument, are of the same nature, are executed on the same day
and are executed on the same place, the volume must be aggregated.
The price of the aggregated transactions is the weighted average
price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 4442
3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079
0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 12 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024